Array BioPharma

About:

Array BioPharma is a biopharmaceutical company focused on the development and commercialization of targeted small molecule drugs.

Website: http://arraybiopharma.com

Twitter/X: arraybiopharma

Top Investors: Deerfield, Frazier Healthcare Partners, Redmile Group

Description:

Array BioPharma is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company partnered drugs are binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology), and tucatinib (partnered with Cascadian Therapeutics). The company is committed to providing therapies to patients. Array BioPharma was founded on 1998 and is headquartered in Boulder, Colorado.

Total Funding Amount:

$412M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Boulder, Colorado, United States

Founded Date:

1998-01-01

Contact Email:

info(AT)arraybiopharma.com

Founders:

Anthony D. Piscopio, Kevin Koch

Number of Employees:

101-250

Last Funding Date:

2017-09-14

IPO Status:

Delisted

© 2025 bioDAO.ai